Comparison of the effects of ketoprofen and flunixin meglumine on the in vitro response of equine peripheral blood monocytes to bacterial endotoxin.
The purpose of this study was to investigate the in vitro effects of flunixin meglumine, a cyclo-oxygenase inhibitor, and ketoprofen, a reported cyclo-oxygenase and lipoxygenase inhibitor, on the synthesis of cyclo-oxygenase end-products thromboxane B2 and prostaglandin E2, lipoxygenase derived 12-hydroxyeicosatetraenoic acid, tumor necrosis factor and tissue factor. Six adult horses were each randomly administered flunixin meglumine (1.1 mg/kg) or ketoprofen (2.2 mg/kg) intravenously every 12 hours with the drug treatments separated by two weeks. Blood samples were obtained prior to initiating treatment, the last day of treatment and for two consecutive days after the termination of treatment for measurement of serum concentrations of thromboxane B2 as well as isolation of peripheral blood monocytes. Quantitation of unstimulated, endotoxin- and calcium ionophore-induced synthesis of thromboxane B2, prostaglandin E2, 12-hydroxyeicosatetraenoic acid, tumor necrosis factor and tissue factor by peripheral blood monocytes was performed in vitro. Both flunixin meglumine and ketoprofen significantly decreased serum concentrations of thromboxane B2 demonstrating in vivo cyclo-oxygenase inhibition. There were no significant differences between drug treatment groups in the in vitro production of thromboxane B2, prostaglandin E2, 12-hydroxy-eicosatetraenoic acid, tumor necrosis factor or tissue factor. This study does not identify significant differences between the effects of flunixin meglumine and ketoprofen.
Jackman
B R
BR
Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens.
Moore
J N
JN
Barton
M H
MH
Morris
D D
DD
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000001:Calcimycin / Q000494:pharmacology; D003002:Clonixin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004731:Endotoxins / Q000097:blood* / Q000633:toxicity; D006734:Horse Diseases / Q000097:blood / Q000517:prevention & control*; D006736:Horses; D006893:Hydroxyeicosatetraenoic Acids / Q000097:blood; D007660:Ketoprofen / Q000494:pharmacology / Q000627:therapeutic use*; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D013925:Thromboplastin / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004731:Endotoxins; D006893:Hydroxyeicosatetraenoic Acids; D014409:Tumor Necrosis Factor-alpha; D000001:Calcimycin; D013929:Thromboxane B2; C014558:flunixin meglumine; D013925:Thromboplastin; D007660:Ketoprofen; D003002:Clonixin